The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients
Eric A. Deckers, Schelto Kruijff, Adrienne H. Brouwers, K. van der Steen, Harald J. Hoekstra, John F. Thompson, David Vállez García, Kevin P. Wevers
Abstract
INTRODUCTION: , metabolic active tumor volume (MATV), and total lesion glycolysis (TLG) in stage IV melanoma in order to understand what these biomarkers reflect and their possible utility for follow-up. METHODS: In 52 stage IV patients the association between PET-derived metrics and the biomarkers S-100B and LDH was assessed and the impact on survival analyzed. RESULTS: . Survival analysis indicated that LDH was the only predictor of melanoma-specific survival. CONCLUSION: F-FDG PET/CT derived MATV and TLG in contrast to LDH, is more often elevated than LDH (71% vs. 21%) and seems to be a better predictor of disease load and disease progression. However, elevated LDH is the only predictor for survival. The biomarkers, S-100B and LDH appear to describe different aspects of the extent of metastatic disease and of tumornecrosis.